Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo.

Demirci, Selami; Dogan, Aysegül; Basak Türkmen, Nese; Telci, Dilek; Çaglayan, Ahmet B; Beker, Mustafa Ç; Kiliç, Ertugrul; Özkan, Ferda; Dede, Bülent; Sahin, Fikrettin

Demirci, Selami; Dogan, Aysegül; Basak Türkmen, Nese; Telci, Dilek; Çaglayan, Ahmet B; Beker, Mustafa Ç; Kiliç, Ertugrul; Özkan, Ferda; Dede, Bülent; Sahin, Fikrettin.

Affiliation

Demirci S; aDepartment of Genetics and Bioengineering, Faculty of Engineering bDepartment of Pathology, Faculty of Medicine, Yeditepe University cDepartment of Physiology, Faculty of Medicine, Istanbul Medipol University, Istanbul dDepartment of Pharmaceutical Toxicology, University of Inonu, Malatya eDepartment of Chemistry, Faculty of Sciences and Arts, Süleyman Demirel University, Isparta, Turkey.

Anticancer Drugs ; 28(8): 869-879, 2017 09.

Article in En | MEDLINE | ID: mdl-28614092

Subject(s)

Poloxalene/pharmacology; Prostatic Neoplasms, Castration-Resistant/drug therapy; Prostatic Neoplasms/drug therapy; Schiff Bases/pharmacology; Animals; Cell Line, Tumor; Coordination Complexes/pharmacology; Gene Expression/drug effects; Humans; Male; Mice, Inbred C57BL; Prostatic Neoplasms/genetics; Prostatic Neoplasms, Castration-Resistant/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Poloxalene / Prostatic Neoplasms / Schiff Bases / Prostatic Neoplasms, Castration-Resistant Limits: Animals / Humans / Male Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2017 Type: Article Affiliation country: Turkey

Fulltext

XML

PubMed Links

Search on Google